Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MCANANEY et al v. SMITHKLINE BEECHAM CORPORATION et al
Case Number:
2:12-cv-05120
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
July 15, 2016
GSK, Indirect Purchasers Plan To Settle Pay-For-Delay Suit
The parties in a lawsuit challenging a pay-for-delay settlement between Teva Pharmaceuticals and GlaxoSmithKline over the latter’s epilepsy drug Lamictal are planning to settle the complaint, according to a letter filed Friday in New Jersey federal court.
-
July 06, 2016
GSK Denied Stay In Antitrust Suit Pending High Court Decision
A New Jersey federal judge on Wednesday denied an attempt by GlaxoSmithKline and Teva Pharmaceuticals Industries Ltd. to pause a legal challenge to their settlement of a pay-for-delay suit over GSK's epilepsy drug Lamictal, a request they made in light of their pending U.S. Supreme Court petition in a parallel case.
-
March 23, 2016
State Claims Too Late For GSK, Teva Lamictal Antitrust Row
A New Jersey federal judge on Tuesday tossed state-law claims brought by indirect purchasers of GlaxoSmithKline's epilepsy drug Lamictal in a pay-for-delay suit over a settlement with Teva Pharmaceutical, concluding that those allegations are time-barred, but allowed Sherman Act claims to proceed.
-
October 06, 2015
GSK, Teva To Take Lamictal Pay-For-Delay Case To High Court
GlaxoSmithKline and Teva told a New Jersey federal court on Monday that they plan to ask the U.S. Supreme Court to review whether a pay-for-delay class action against them should be nixed because their settlement over Lamictal patents didn't involve a cash payment.
-
September 09, 2013
GSK, Teva Say Lamictal Deal Doesn't Break Antitrust Law
GlaxoSmithKline LLC and Teva Pharmaceutical Industries Ltd. urged a New Jersey federal judge Friday to dismiss claims by indirect purchasers of GSK's epilepsy drug Lamictal accusing the companies of entering a pay-for-delay settlement that was unlawful and anti-competitive.